Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Celanese (CE)

Celanese Q2 adjusted EPS falls to $1.44 from $2.38; Q3 outlook $1.10 to $1.40

Mixed Impact 3 of 5 earnings Written later

Celanese reported second quarter 2025 net sales of $2.5 billion, up 6% from the first quarter but below $2.65 billion a year earlier, and adjusted earnings per share of $1.44 versus $2.38 in the second quarter of 2024. GAAP diluted EPS was $1.90, aided by a $77 million tax benefit. The company expects third quarter adjusted EPS of $1.10 to $1.40 and reaffirmed 2025 free cash flow of $700 to $800 million, citing softening demand in the second half.

Key points

  • Adjusted EPS was $1.44 versus $2.38 in Q2 2024; GAAP diluted EPS was $1.90, including a $77 million tax benefit
  • Net sales were $2,532 million versus $2,651 million in Q2 2024, and up 6% from $2,389 million in Q1 2025
  • Third quarter 2025 adjusted EPS is expected at $1.10 to $1.40; 2025 free cash flow target is $700 to $800 million, with Q2 free cash flow at $311 million

The filing

CompanyCelanese (CE)
Form8-K, current report
Filed with the SECAug 11, 2025, 4:16 PM ET
Accession number0001306830-25-000171

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.